Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This study is for women with confirmed hormone receptor positive HER-2 negative advanced
breast cancer with evidence of disease resistance to an aromatase inhibitor.
The purpose of this study is to determine how well these medications work together and/or if
they have any side effects in patients with hormone-receptor positive metastatic breast
cancer who have demonstrated progression of disease after first line hormonal therapy.
This research is being done to determine if taking an already approved medicine (aromatase
inhibitor) in combination with a new medication (dovitinib) results in better outcomes for
patients with this disease.
Both dovitinib and an aromatase inhibitor are pills that will be taken at home.